Among adults with overweight or obesity, treatment with GLP-1 receptor agonists and incretin-based therapies along with lifestyle changes is associated with an average 9.53 percentage point decrease in body weight, which aligns with weight loss measured in kilograms but is calculated differently.
See the scientific wording
GLP-1 receptor agonist and incretin-based therapies combined with lifestyle interventions are associated with an average reduction of 9.53 percentage points in body weight among adults with overweight or obesity, a finding consistent with kilogram-scale results but analytically distinct due to differences in measurement scale and clinical interpretation.
Very strong evidence
One good-quality study supports this claim.
What the research says
1 study reviewedSupporting (1)
Systematic Review With Meta-AnalysisMeta-analysis2026
When people with extra weight take GLP-1 medications and also eat better and exercise, they typically lose about 9.5% of their body weight on average — and this study directly found that same number. It’s not the same as losing 10 kilograms, but both numbers are true and measure weight loss in different ways.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
A hormone-like drug binds to receptors in the brain and stomach, making the person feel full sooner and stay full longer, which reduces food intake. The stomach empties more slowly, keeping food in longer and further reducing hunger. At the same time, the body shifts from burning sugar to burning fat for energy, especially when calories are low, which breaks down fat stores more efficiently and prevents the metabolism from slowing down too much.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
Among adults with overweight or obesity, treatment with GLP-1 receptor agonists and incretin-based therapies along with lifestyle changes is associated with an average 9.53 percentage point decrease in body weight, which aligns with weight loss measured in kilograms but is calculated differently.
Mechanism
1 studyA drug activates brain signals that make you feel full faster and keep food in your stomach longer, so you eat less. At the same time, your body switches from burning sugar to burning fat for energy, especially when you're eating fewer calories, which breaks down fat stores more efficiently and keeps your metabolism from slowing down. This combination causes significant fat loss without losing much muscle.
A hormone-like drug binds to receptors in the brain and stomach, making the person feel full sooner and stay full longer, which reduces food intake. The stomach empties more slowly, keeping food in longer and further reducing hunger. At the same time, the body shifts from burning sugar to burning fat for energy, especially when calories are low, which breaks down fat stores more efficiently and prevents the metabolism from slowing down too much.
GLP-1 receptor agonists bind to receptors on neurons in the hypothalamus and brainstem, increasing signals that suppress hunger and decreasing signals that stimulate hunger
GLP-1 receptor agonists slow gastric emptying, prolonging gastric distension and enhancing vagal afferent signaling to the brain to reinforce satiety
Reduced caloric intake creates a sustained energy deficit, triggering mobilization of adipose tissue stores and reduction in fat mass
GLP-1 receptor agonists activate hepatic and adipose tissue receptors, increasing lipolysis and free fatty acid release into circulation
Free fatty acids are transported to the liver and undergo beta-oxidation, producing ketone bodies and shifting systemic energy substrate utilization from glucose to fat
Increased fat oxidation reduces reliance on glucose and attenuates the adaptive reduction in resting metabolic rate during energy restriction
Less supported by current evidence, but not ruled out
The drug stimulates the pancreas to release more insulin when blood sugar is high and reduces the release of a hormone that tells the liver to make more sugar. This lowers blood sugar levels and reduces fat storage, allowing the body to burn fat more effectively.
GLP-1 receptor agonists bind to receptors on pancreatic beta-cells, activating cAMP/PKA signaling to enhance glucose-dependent insulin secretion
GLP-1 receptor agonists bind to receptors on pancreatic alpha-cells, suppressing glucagon secretion and reducing hepatic glucose production
Improved glycemic control reduces lipotoxicity and insulin resistance, promoting preferential mobilization of fat over muscle tissue during energy deficit
Physical activity, especially strength training, sends signals to muscles to build and maintain protein, preventing muscle loss even when the body is burning fat due to reduced calorie intake.
Mechanical tension and metabolic stress from resistance and aerobic exercise activate mechanosensors in skeletal muscle
Mechanosensor activation triggers PI3K/Akt/mTOR signaling pathways to increase muscle protein synthesis and reduce protein breakdown
Improved insulin sensitivity and nutrient partitioning direct glucose and amino acids toward muscle tissue instead of fat storage
Preservation of lean mass occurs despite systemic energy deficit, maintaining metabolic rate and physical function
Evidence from Studies
Supporting (1)
Community contributions welcome
GLP-1RA- and Incretin-Based Therapies Within Lifestyle Interventions for Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis
When people with extra weight take GLP-1 medications and also eat better and exercise, they typically lose about 9.5% of their body weight on average — and this study directly found that same number. It’s not the same as losing 10 kilograms, but both numbers are true and measure weight loss in different ways.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review and Meta-Analysis of GLP-1 Receptor Agonists and Incretin Therapies Combined with Lifestyle Interventions for Weight Loss in Adults with Overweight or Obesity
Population: Adults with overweight or obesity; Intervention: GLP-1 receptor agonists and incretin-based therapies combined with standardized lifestyle interventions; Comparator: Placebo or lifestyle interventions alone; Outcome: Percentage change in body weight; Duration: Minimum 12 months
Double-Blind Randomized Controlled Trial of GLP-1 Receptor Agonist Plus Lifestyle Intervention vs Lifestyle Intervention Alone for Weight Loss in Adults with Obesity
Population: Adults with BMI ≥27 kg/m²; Intervention: GLP-1 receptor agonist plus structured lifestyle program; Comparator: Placebo plus identical lifestyle program; Outcome: Percentage change in body weight at 52 weeks; Duration: 52 weeks
Prospective Cohort Study of GLP-1 Receptor Agonist Use and Weight Change in Adults with Overweight or Obesity in Primary Care Settings
Population: Adults with overweight or obesity initiating GLP-1 receptor agonist therapy; Comparator: Adults with similar baseline characteristics not receiving therapy; Outcome: Percentage weight change at 6, 12, and 24 months; Duration: 24 months
Cross-Sectional Analysis of Body Weight Percentage Change in Adults with Obesity Receiving GLP-1 Receptor Agonists and Lifestyle Counseling
Population: Adults with overweight or obesity currently on GLP-1 receptor agonists and lifestyle interventions; Outcome: Current percentage weight change from baseline; Duration: Single time point
Case Report of Weight Loss of 9.53 Percentage Points in an Individual with Obesity Treated with GLP-1 Receptor Agonist and Lifestyle Intervention
Population: Single adult with overweight or obesity; Intervention: GLP-1 receptor agonist and lifestyle changes; Outcome: Percentage weight loss; Duration: Variable